Search hospitals > California > Beverly Hills
Tower Cancer Research Foundation
Claim this profileBeverly Hills, California 90211
Global Leader in Cancer
Global Leader in Non-Small Cell Lung Cancer
Conducts research for Lung Cancer
Conducts research for Lymphoma
Conducts research for Breast Cancer
80 reported clinical trials
15 medical researchers
Summary
Tower Cancer Research Foundation is a medical facility located in Beverly Hills, California. This center is recognized for care of Cancer, Non-Small Cell Lung Cancer, Lung Cancer, Lymphoma, Breast Cancer and other specialties. Tower Cancer Research Foundation is involved with conducting 80 clinical trials across 128 conditions. There are 15 research doctors associated with this hospital, such as Jun Gong, MD, Andrew Hendifar, MD, Yuan Yuan, MD PhD, and Leslie Ballas.Area of expertise
1Cancer
Global LeaderHER2 positive
ER positive
Stage IV
2Non-Small Cell Lung Cancer
Global LeaderStage IV
Stage III
EGFR positive
Top PIs
Jun Gong, MDCedars-Sinai Medical Center3 years of reported clinical research
Studies Colorectal Cancer
Studies Cancer
18 reported clinical trials
35 drugs studied
Andrew Hendifar, MDCedars-Sinai Medical Center4 years of reported clinical research
Studies Pancreatic Cancer
Studies Adenocarcinoma
19 reported clinical trials
38 drugs studied
Yuan Yuan, MD PhDCity of Hope Medical Center1 year of reported clinical research
Expert in Breast Cancer
Studies Colorectal Cancer
14 reported clinical trials
46 drugs studied
Leslie BallasUSC / Norris Comprehensive Cancer Center5 years of reported clinical research
Studies Prostate Cancer
Studies Adenocarcinoma
10 reported clinical trials
25 drugs studied
Clinical Trials running at Tower Cancer Research Foundation
Breast Cancer
Diffuse Large B-Cell Lymphoma
Neuroendocrine Tumors
Lung Cancer
Colorectal Cancer
Cancer
Squamous Cell Carcinoma
Lymphoma
Recurrence
B-Cell Lymphoma
Radiation and HER2-Targeted Therapy
for Breast Cancer
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Recruiting2 awards Phase 315 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Tower Cancer Research Foundation?
Tower Cancer Research Foundation is a medical facility located in Beverly Hills, California. This center is recognized for care of Cancer, Non-Small Cell Lung Cancer, Lung Cancer, Lymphoma, Breast Cancer and other specialties. Tower Cancer Research Foundation is involved with conducting 80 clinical trials across 128 conditions. There are 15 research doctors associated with this hospital, such as Jun Gong, MD, Andrew Hendifar, MD, Yuan Yuan, MD PhD, and Leslie Ballas.